文献速递神经肿瘤

IDH1 p.R132H 循环肿瘤DNA与D-2-羟基戊二酸作为IDH突变型胶质瘤患者脑脊液生物标志物

IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
PubMed 文献 · J Neurooncol · 2022-07-11

研究纳入48例浸润性胶质瘤患者(6例IDH突变型、42例IDH野生型)的57份脑脊液样本,采用ddPCR检测脑脊液ctDNA中IDH1 p.R132H突变频率,液相色谱-质谱法测定2HG水平。IDH突变型患者脑脊液总2HG、D-2HG水平及D/L-2HG比值显著高于IDH野生型,D-2HG水平及D/L-2HG比值在IDH突变型中与肿瘤体积相关。作者认为ddPCR检测IDH1 p.R132H突变及脑脊液D-2HG水平升高可能有助于识别IDH突变型胶质瘤。

要点

  • IDH突变型患者9份样本中7份检出ctDNA,其中5份检出IDH1 p.R132H突变,突变频率0.3%至39.95%。
  • IDH突变型患者脑脊液总2HG、D-2HG水平及D/L-2HG比值显著高于IDH野生型患者。
  • IDH突变型患者中D-2HG水平及D/L-2HG比值与总肿瘤体积相关,IDH野生型患者中无此相关。

核心结论

  • 作者认为,ddPCR检测脑脊液ctDNA中IDH1 p.R132H突变及脑脊液D-2HG水平升高可能有助于识别IDH突变型胶质瘤。
  • 作者认为,D-2HG水平及D/L-2HG比值在IDH突变型胶质瘤患者中与肿瘤体积相关。
  • 作者提出需要更大规模的前瞻性研究来验证这些发现。

研究设计与样本

  • 研究收集浸润性胶质瘤患者的脑脊液,采用液相色谱-质谱法测定2HG水平,采用微滴数字PCR(ddPCR)测定脑脊液ctDNA中IDH1 p.R132H突变等位基因频率(MAF),并从标准诊疗磁共振图像测量肿瘤体积。
  • 研究共纳入48例患者(6例IDH突变型、42例IDH野生型),共57份样本(IDH突变型9份、IDH野生型48份)。

主要发现

  • IDH突变型患者9份样本中7份检出ctDNA,其中5份检出IDH1 p.R132H突变,MAF范围为0.3%至39.95%。
  • 脑脊液总2HG水平、D-2HG水平及D/L-2HG比值在IDH突变型胶质瘤患者中显著高于IDH野生型胶质瘤患者。
  • D-2HG水平及D/L-2HG比值在IDH突变型胶质瘤患者中与总肿瘤体积相关,在IDH野生型胶质瘤患者中不相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者提出需要更大规模的前瞻性研究来验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We aimed to evaluate IDH1 p.R132H mutation and 2-hydroxyglutarate (2HG) in cerebrospinal fluid (CSF) as biomarkers for patients with IDH-mutant gliomas. METHODS: CSF was collected from patients with infiltrating glioma, and 2HG levels were measured by liquid chromatography-mass spectrometry. IDH1 p.R132H mutant allele frequency (MAF) in CSF-ctDNA was measured by digital droplet PCR (ddPCR). Tumor volume was measured from standard-of-care magnetic resonance images. RESULTS: The study included 48 patients, 6 with IDH-mutant and 42 with IDH-wildtype gliomas, and 57 samples, 9 from the patients with IDH-mutant and 48 from the patients with IDH-wildtype gliomas. ctDNA was detected in 7 of the 9 samples from patients with IDH-mutant glioma, and IDH1 p.R132H mutation was detected in 5 of the 7 samples. The MAF ranged from 0.3 to 39.95%. Total 2HG level, D-2HG level, and D/L-2HG ratio in CSF were significantly higher in patients with IDH-mutant gliomas than in patients with IDH-wildtype gliomas. D-2HG level and D/L-2HG ratio correlated with total tumor volume in patients with IDH-mutant gliomas but not in patients with IDH-wildtype gliomas. CONCLUSION: Our results suggest that detection of IDH1 p.R132H mutation by ddPCR and increased D-2HG level in CSF may help identify IDH-mutant gliomas. Our results also suggest that D-2HG level and D/L-2HG ratio correlate with tumor volume in patients with IDH-mutant gliomas. Further prospective studies with larger cohorts are needed to validate these findings.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Fujita Y, Nunez-Rubiano L, Dono A, et al. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas. J Neurooncol. 2022. PMID: 35816267. doi:10.1007/s11060-022-04060-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。